EMPHACIS Trial

The EMPHACIS trial (Evaluation of MTA in Mesothelioma in a Phase III Study with Cisplatin) was a landmark international clinical trial published in 2003 that established the combination of pemetrexed (Alimta) and cisplatin as the first standard chemotherapy regimen for malignant pleural mesothelioma. The study compared cisplatin alone to cisplatin plus pemetrexed in 456 patients and showed that the combination significantly improved survival, response rates, and lung function. It led directly to the FDA approval of pemetrexed for mesothelioma in 2004.

Origin

The trial was designed and run by Eli Lilly and Company, the maker of pemetrexed, with lead investigator Dr. Nicholas Vogelzang. Results were published in the Journal of Clinical Oncology in July 2003 under the title "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma." The acronym EMPHACIS reflects the trial's focus on MTA (multi-targeted antifolate, the original name for pemetrexed) in combination with cisplatin.

Significance in Asbestos Context

For nearly two decades after EMPHACIS, the cisplatin-pemetrexed regimen it validated was the only chemotherapy proven to extend life in mesothelioma patients, and it remains a widely used first-line treatment. Patients diagnosed with pleural mesothelioma will almost certainly see this regimen discussed by their oncologist, often alongside newer options like immunotherapy (the Checkmate 743 nivolumab-ipilimumab combination became an alternative first-line standard in 2020). In legal cases, the existence and limitations of this treatment, median survival of about 12.1 months in the trial versus 9.3 months with cisplatin alone, are routinely cited by medical experts when describing prognosis, the cost and burden of treatment, and the damages associated with a mesothelioma diagnosis.

Example Sentence

After her mesothelioma diagnosis, the oncologist recommended the cisplatin-pemetrexed regimen established by the EMPHACIS trial as a first-line treatment option.

Related Terms

Pemetrexed (Alimta), Cisplatin, Malignant Pleural Mesothelioma, Checkmate 743, First-Line Chemotherapy, Median Overall Survival

Notes

• Ask your oncologist whether you are a candidate for cisplatin-pemetrexed, carboplatin-pemetrexed (a gentler substitute for patients who cannot tolerate cisplatin), or the newer nivolumab-ipilimumab immunotherapy combination, and whether bevacizumab or a clinical trial should be added.
• Keep complete records of every chemotherapy cycle, including drug names, doses, side effects, hospitalizations, and supportive medications. These documents support both medical care coordination and the medical-expenses portion of a legal claim.
• The EMPHACIS survival figures are now over 20 years old; ask whether more recent data, biomarker testing (such as PD-L1 or BAP1 status), or trial enrollment might offer better options for your specific subtype (epithelioid, sarcomatoid, or biphasic).
• If a treating oncologist references EMPHACIS or "standard of care" chemotherapy in your records, those notes can be useful for your legal team in documenting the seriousness of the diagnosis and the medical necessity of treatment.